Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
A notice concerning Travere Therapeutics, Inc. (TVTX) lists Officer Jula Inrig's proposed sale of 311 common shares, with an aggregate market value of $13,668.45 and an approximate sale date of May 6, 2026. Morgan Stanley Smith Barney LLC is named as the broker. The notice gives May 28, 2025 as the Rule 10b5-1 plan adoption or instruction date and lists 311 performance shares acquired from the issuer on May 4, 2026.
Travere Therapeutics, Inc. (TVTX) officer Eric M. Dube reported a proposed sale of 22,500 common shares, with an aggregate market value of $988,875.00 and an approximate sale date of May 6, 2026. The shares were acquired through restricted stock vesting on May 4, 2026, as compensation. The listed date of plan adoption or instruction for reliance on Rule 10b5-1 is June 16, 2025. Dube's other reported sales in the preceding three months were 60,000 shares on February 20, 2026, 60,000 on April 1, 2026, and 64,000 on April 15, 2026.
Travere Therapeutics, Inc. officer William E. Rote reported an intended sale of 2,763 common shares, with an aggregate market value of $121,433.85 and an approximate sale date of May 6, 2026. The shares were acquired from the issuer through restricted stock vesting on May 4, 2026, as compensation. Rote also reported selling 9,100 common shares on April 22, 2026, for gross proceeds of $355,719.
Travere Therapeutics, Inc. (TVTX) officer Christopher Cline reported a proposed sale of 2,181 common shares, with an aggregate market value of $101,743.65, on approximately May 5, 2026.
The shares were acquired through performance restricted stock unit vesting on May 4, 2026, as compensation. The sale is mandated under the issuer’s equity incentive plans to fund tax withholding through a brokerage firm designated by the issuer; it is not a discretionary trade. Morgan Stanley Smith Barney is listed as the broker. Elizabeth E. Reed signed as attorney-in-fact for Christopher Cline.
Travere Therapeutics, Inc. officer Elizabeth E. Reed reported a proposed sale of 2,174 common shares, with an aggregate market value of $101,417.10 and an approximate sale date of May 5, 2026. The shares were acquired from the issuer on May 4, 2026 through performance restricted stock unit vesting as compensation. The sale is required to cover tax withholding on the vested units under the issuer’s equity incentive plans; it is described as not discretionary.
Jula Inrig, an officer of Travere Therapeutics, Inc. (TVTX), reported a proposed sale of 2,174 common shares, with an aggregate market value of $101,417.10 and an approximate sale date of May 5, 2026. The shares were acquired through vesting of performance restricted stock units on May 4, 2026. The remarks state that the sale is required to fund tax withholding under the issuer’s equity incentive plans and is not a discretionary trade.
Travere Therapeutics, Inc. (TVTX) officer Peter Heerma is named in a notice covering the proposed sale of 2,174 common shares, with an approximate sale date of May 5, 2026, and an aggregate market value of $101,417.10. The shares came from performance restricted stock unit vesting on May 4, 2026. The notice says the sale is mandated by the issuer’s election under its equity incentive plans to fund tax withholding through an issuer-designated broker, and is not discretionary. During the prior three months, Peter Heerma sold 7,215 common shares on April 14, 2026, for gross proceeds of $302,515.98.
Roy Baynes reported a proposed sale of 4,500 shares of Common Stock under Rule 144 tied to a stock option exercise dated 05/05/2026. The filing also lists three prior open-market dispositions by Roy Baynes: 9,750 shares on 05/01/2026 for $431,145.00; 32,750 shares on 04/14/2026 for $1,352,130.00; and 10,000 shares on 04/06/2026 for $330,000.00.
Travere Therapeutics is offering $400,000,000 aggregate principal amount of % convertible senior notes due 2032, with an underwriter option for up to $60,000,000 additional notes, subject to completion. The notes mature on May 15, 2032, bear stated cash interest (rate not specified in the excerpt) payable semi-annually, and are convertible into cash, shares of common stock or a combination at Travere’s election under specified conditions.
Conversion is permitted only upon specified triggers including a sustained common-stock price condition, a note trading-price test, certain corporate events, a call for redemption and during a conversion period beginning February 17, 2032. Notes are redeemable at Travere’s option on or after May 21, 2029 if Nasdaq trading thresholds are met. The notes will be unsecured senior obligations and will rank equal with other unsecured indebtedness and be structurally subordinated to subsidiaries’ liabilities. Travere does not intend to list the notes; its common stock traded at $44.91 on May 4, 2026. This prospectus supplement is preliminary and subject to completion (dated May 5, 2026).
Travere Therapeutics reported higher revenue but continued losses for the quarter ended March 31, 2026. Total revenue reached $127.2 million, up from $81.7 million a year earlier, driven mainly by FILSPARI sales.
Net product sales were $124.5 million, including $105.2 million from FILSPARI and $19.3 million from tiopronin products. The company recorded a net loss of $37.1 million, versus $41.2 million in the prior-year quarter, or $(0.40) per share.
Operating expenses rose to $164.1 million, reflecting higher research and development and selling, general and administrative costs, as well as royalty expense. Travere ended the quarter with $78.4 million in cash and cash equivalents and $186.3 million in marketable debt securities, against $312.1 million of convertible debt.
In April 2026, after quarter-end, the FDA granted full approval of FILSPARI for FSGS, making it the first approved medicine for this disease. Travere also restarted enrollment in its Phase 3 HARMONY study of pegtibatinase for classical homocystinuria and dosed the first new patient following the restart.